Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome
Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
A subset of patients suffering from chronic fatigue syndrome exhibit symptoms of neurally
mediated hypotension. While the underlying pathophysiology of chronic fatigue syndrome is not
precisely understood, a dysfunction of the autonomic nervous system is thought to play a role
in this subset of patients. In several small studies, subjects within this subset have noted
improvement in their chronic fatigue symptoms when treated for their neurally mediated
hypotension. As droxidopa acts on the autonomic nervous system and has been shown to
ameliorate symptoms of neurally mediated hypotension, it is hypothesized that droxidopa could
aid in the treatment of chronic fatigue symptoms.
Neurally mediated hypotension has been associated with patients suffering from chronic
fatigue syndrome. Droxidopa meanwhile has been approved in Japan for the treatment of the
symptoms of neurogenic orthostatic hypotension. As such, it is hypothesized that regulating
the autonomic nervous system in patients with Chronic fatigue syndrome may prove to be
clinically beneficial.